Magnesium Inhibits Platelet Activity - An In Vitro Study

Summary

The in vitro effect of magnesium (Mg) on platelet aggregation and platelet release function was evaluated in healthy volunteers. Platelet aggregation was induced with collagen, ADP, or thrombin after incubation of the sample with saline or increasing concentrations of magnesium sulphate (MgSO₄) (0.5-8.0 mM). Mg showed a dose-dependent inhibition of platelet aggregation in whole blood, platelet rich plasma and washed platelets. An antiaggregatory effect was also present with low Mg concentrations. Statistically significant inhibition of the mean aggregation response was obtained in 83% of the different media and agonists tested following the addition of 1.0 mM Mg. The remaining 17% were significantly inhibited with the addition of 2.0 mM Mg. The platelet synthesis of thromboxane A₂ and release of beta-thrombo-globulin were also inhibited by Mg, in a dose-dependent manner. In order to evaluate if any of these effects were modified by conventional antithrombotic treatment with low-dose acetylsalicylic acid (ASA), volunteers were asked to meet on two consecutive days. On day 2 the participants were given 300 mg ASA orally, one hour prior to blood sampling. The Mg mediated effects were present independent of this pretreatment with ASA. Following stimulation with collagen a synergistic effect of Mg and ASA was demonstrated on platelet aggregation. The platelet inhibiting effect demonstrated in this study may in part explain the beneficial effect of Mg infusion in some patients with acute myocardial infarction. The effect of Mg infusion, given alone or administered simultaneously with ASA, should also be evaluated in other arterial thrombotic disease states.

• References

• 1 Falk E. Why do plaques rupture?. Circulation 1992; 86 (Suppl. 03) III30-III42
• 2 Kristensen SD, Martin JF. Platelet heterogeneity and coronary thrombosis. Platelets 1991; 2: 11-17
• 3 Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985; 5: 175B-184B
• 4 Nadler J, Malayan S, Luong H, Shaw L, Natarajan RD, Rude RK. Evidence that intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care 1992; 15: 835-841
• 5 Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991; 303: 1499-1503
• 6 Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial. (LIMIT-2) Lancet 1992; 339: 1553-1558
• 7 ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected myocardial infarction. Lancet 1995; 345:C: 669-685
• 8 Acland R. Prevention of thrombosis in microvascular surgery by the use of magnesium sulphate. Br J Plastic Surgery 1972; 25: 292-299
• 9 Adams JH, Mitchell JRA. The effects of agents which modify platelet behavior and of magnesium ions on thrombus formation in vivo. Thromb Haemost 1979; 42: 603-610
• 10 Gertz SD, Rebecka S, Wajnberg AK, Uretzky G. Effect of magnesium sulphate on thrombus formation following partial arterial constriction: implications for coronary vasospasms. Magnesium 1987; 6: 225-235
• 11 Hughes A, Tonks RS. Magnesium, adenosine diphosphate and blood platelets. Nature 1966; 210: 106-107
• 12 Heptinstall S. The use of a chelating ion-exchange resin to evaluate the effects of the extracellular calcium concentration on adenosine diphosphate induced aggregation on human blood platelets. Thromb Haemost 1976; 36: 208-220
• 14 Watson KL, Moldow CF, Ogbum PL, Jacob HS. Magnesium sulphate: rationale for its use in preeclampsia. Proc Natl Acad Sci USA 1986; 83: 1075-1078
• 15 Hwang DL, Yen CF, Nadler JL. Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. Am J Hypertension 1992; 5: 700-706
• 16 Gawaz M, Ott I, Reininger AJ, Neumann FJ. Effect of magnesium on platelet aggregation and adhesion. Thromb Haemost 1994; 72: 912-918
• 17 Hardy E, Heptinstall S, Rubin PC, Horn EH. Effects of raised extracellular magnesium on platelet reactivity. Platelets 1995; 6: 346-353
• 18 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-360
• 19 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease Lancet 1990; 336: 827-830
• 20 Antiplatelet trialist collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 1994; 308: 81-106
• 21 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacological Methods 1980; 3: 135-158
• 22 Bom GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
• 30 Radomski M, Moncada S. An improved method for washing human platelets with prostacyclin. Thromb Res 1983; 30: 383-389
• 24 Blackwell GJ, Radomski M, Vargas JR, Moncada S. Prostacyclin prolongs viability of human washed platelets. Biochim Biophys Acta 1982; 718: 60-65
• 25 Marki WE, Wallis RB. The anticoagulant and antithrombotic properties of himdins. Thromb Haemost 1990; 64: 344-348
• 26 Markwardt F. Hirudin and its derivatives as anticoagulant agents. Thromb Haemost 1991; 66: 141-152
• 27 Abbate R, Boddi M, Prisco D, Gensini GF. Ability of whole blood aggregometer to detect platelet hyperaggregability. Am J Clin Pathol 1989; 91: 159-163
• 28 Martin JF, Bath PMW. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-1411
• 29 Smyth DW, Martin JF, Michalis L, Bucknall CA, Jewitt DE. Influence of platelet size before coronary angioplasty and subsequent restenosis. Eur J Clin Invest 1993; 23: 361-367
• 30 Wallen NH, Held C, Rehnquist N, Hjemdahl P. Impact of treatment with acetylsalicylic acid on the proaggregatory effect of adrenaline in vitro in patients with stable angina pectoris: influence of the anticoagulant. Cli Sci 1993; 85: 577-583
• 31 Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-651
• 32 Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of the concentration of Ca²⁺ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989; 62: 968-976
• 33 Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of α,-granules or lysosomes from human platelets. Cli Sci 1994; 87: 575-580
• 34 Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet α ,-granule release. Blood 1993; 82: 505-512
• 35 Iseri LT, French JH. Magnesium: Nature's physiologic calcium blocker. Am Heart J 1984; 108: 188-193
• 36 Woods KL. Possible pharmacological actions of magnesium in acute myocardial infarction. Br J Pharmacol 1991; 32: 3-10
• 37 Hardy E, Glenn J, Heptinstall S, Rubin PC, Horn EH. Magnesium modifies the responses of platelets to inhibitory agents which acts via cAMP. Thromb Haemost 1995; 74: 1132-1137